We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    migraine actipatch
Previous Study | Return to List | Next Study

Migraine Prevention Using ActiPatch (PSWT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03166046
Recruitment Status : Completed
First Posted : May 24, 2017
Last Update Posted : August 2, 2018
Information provided by (Responsible Party):
BioElectronics Corporation

Brief Summary:
Chronic pain is now widely understood to be due to central sensitization, which leads to exaggerated pain perception. Migraine is no exception, since it is well known that sensitization of the trigeminovascular pain pathway can occur during a migraine attach. There is early evidence that ActiPatch can help mitigate this sensitization, so this study is being conducted to determine the efficacy of ActiPatch in preventing chronic, episodic migraines.

Condition or disease Intervention/treatment Phase
Migraine Device: Pulsed Shortwave Therapy Device: Placebo Pulsed Shortwave therapy Not Applicable

Detailed Description:

Migraine is a common neurological disorder characterized by episodes of unilateral or bilateral headache lasting for hours to days, which may be accompanied by photophobia, phonophobia, nausea and vomiting. Pharmacological management is the first treatment option for subjects with migraine. However, some patients do not tolerate acute and/or prophylactic medicine due to side effects or contraindications due to comorbidity of other diseases or due to a wish to avoid medication for other reasons. The risk of medication overuse due to frequent migraine attacks represents a major health hazard with direct and indirect cost concerns. The prevalence of medication overuse headache is 1 -2% in the general population, that is, about half the population suffering chronic headache (15 headache days or more per month) have medication overuse headache.It is well-known that a primary brain dysfunction leads to episodic activation and sensitization of the trigeminovascular pain pathway during attacks. However, a functional and anatomic relationship exists between peripheral afferent nerves supplying the head and neck and the brainstem, subcortical and higher order brain processing centers. There is some evidence that interventions targeting peripheral nerves are able to modulate neuronal circuits involved in pain control and that they could be useful in some selected patients with migraine.

Supraorbital neurostimulation (tSNS) of the upper branches of the trigeminal nerves was found superior to sham stimulation for episodic migraine prevention in a previous randomized trial in a large cohort of patients with migraine. In this study the pulsed shortwave device will be incorporated in a wrap which will enable easy placement of the device in the desired located which will be over the supratrochlear and supraorbital branches of the ophthalmic nerve.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 45 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Randomized, double blind, placebo controlled trial using an active pulsed shortwave therapy device or placebo pulsed shortwave therapy device
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description: Coded devices that are identical in appearance and function. Placebo device does not emit electromagnetic field. Active device electromagnetic field is sub-sensory.
Primary Purpose: Treatment
Official Title: Migraine Prevention Using Pulsed Shortwave Therapy
Actual Study Start Date : June 1, 2017
Actual Primary Completion Date : April 1, 2018
Actual Study Completion Date : April 30, 2018

Resource links provided by the National Library of Medicine

MedlinePlus Genetics related topics: Migraine
MedlinePlus related topics: Migraine

Arm Intervention/treatment
Active Comparator: Study Group
Subjects will use the active pulsed shortwave therapy device (ActiPatch) as a prophylactic treatment for episodic migraine
Device: Pulsed Shortwave Therapy
Stimulation of the supratrochlear and supraorbital branches of the ophthalmic nerve.
Other Name: ActiPatch

Placebo Comparator: Control Group
Subjects will use the placebo pulsed shortwave therapy device (Placebo ActiPatch) as a prophylactic treatment for episodic migraine
Device: Placebo Pulsed Shortwave therapy
Placebo Stimulation of the supratrochlear and supraorbital branches of the ophthalmic nerve.
Other Name: Placebo ActiPatch

Primary Outcome Measures :
  1. Migraine frequency [ Time Frame: 4 weeks ]
    frequency of migraine attacks

  2. Migraine duration [ Time Frame: 4 weeks ]
    Duration of migraine attacks

Secondary Outcome Measures :
  1. Migraine intensity measured with Visual Analogue Pain Score [ Time Frame: 4 weeks ]
    Migraine intensity measured with visual analogue pain score (VAS scores)

  2. Headache disability measured with Headache Impact Test [ Time Frame: 4 weeks ]
    Headache impact test (HIT-6)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Participant is willing and able to give informed consent for participation in the trial.
  • In the Investigator's opinion, is able and willing to comply with all trial requirements.
  • Male or female ages 18 or above with migraine headache
  • 3 or greater occurrences of migraine per month
  • no prior use of neuromodulation for migraine headache

Exclusion Criteria:

  • Female participant who is pregnant
  • prior use of neuromodulation for migraine headache
  • Laminectomy, laminotomy or discectomy within 12 months of enrollment.
  • Active psychiatric disorders will be excluded (e.g. use of antipsychotic medication, bipolar disorder, schizophrenia).
  • Patients diagnosed with history of significant mood disorder will be excluded (e.g., depression or anxiety with adequate control would be acceptable).
  • Scheduled elective surgery or other procedures requiring general anaesthesia during the trial.
  • Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant's ability to participate in the trial.
  • Participants who have participated in another research trial involving an investigational product in the past 12 weeks.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03166046

Layout table for location information
United States, Indiana
Eppley Group
Indianapolis, Indiana, United States, 46032
Sponsors and Collaborators
BioElectronics Corporation
Layout table for investigator information
Study Director: Sree Koneru, Ph.D. BioElectronics Corporation
Principal Investigator: Barry Eppley, MD Eppley Group
Study Chair: Ian Rawe, Ph.D. BioElectronics Corporation
Layout table for additonal information
Responsible Party: BioElectronics Corporation
ClinicalTrials.gov Identifier: NCT03166046    
Other Study ID Numbers: SAIRB-17-0021
First Posted: May 24, 2017    Key Record Dates
Last Update Posted: August 2, 2018
Last Verified: August 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Migraine Disorders
Headache Disorders, Primary
Headache Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases